Glioblastoma Treatment Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

Glioblastoma Treatment Drug Market Report: Trends, Forecast and Competitive Analysis to 2030


Glioblastoma Treatment Drug Trends and Forecast

The future of the global glioblastoma treatment drug market looks promising with opportunities in the hospital, cancer research organization, long term care center, and diagnostic center markets. The global glioblastoma treatment drug market is expected to reach an estimated $1.3 billion by 2030 with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising prevalence of glioblastoma, growing adoption of gene and cell therapies, and expanding development of chemotherapy drugs.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Glioblastoma Treatment Drug by Segment

The study includes a forecast for the global glioblastoma treatment drug by drug class, distribution channel, and region.

Glioblastoma Treatment Drug Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:
  • Antineoplastic
  • VEGF/VEGFR Inhibitors
  • Alkylating Agents
  • Miscellaneous Antineoplastic
Glioblastoma Treatment Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
  • Hospitals
  • Cancer Research Organizations
  • Long Term Care Centers
  • Diagnostic Centers
  • Others
Glioblastoma Treatment Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:
  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World
List of Glioblastoma Treatment Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glioblastoma treatment drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glioblastoma treatment drug companies profiled in this report include-
  • Gene Therapy
  • Virus
  • Kinase Inhibitor
  • Glioma Steam Cell Targeting
  • MiRNA Targeting
  • Pfizer
  • Roche Holding
  • Novartis
  • Johnson & Johnson
  • Merck
Glioblastoma Treatment Drug Market Insights

Lucintel forecasts that alkylating agent will remain the largest segment over the forecast period.

Within this market, hospital will remain the largest segment over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Glioblastoma Treatment Drug Market

Market Size Estimates: Glioblastoma treatment drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glioblastoma treatment drug market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Glioblastoma treatment drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, distribution channels, and regions for the glioblastoma treatment drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glioblastoma treatment drug market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the glioblastoma treatment drug market size?

Answer: The global glioblastoma treatment drug market is expected to reach an estimated $1.3 billion by 2030.

Q2. What is the growth forecast for glioblastoma treatment drug market?

Answer: The global glioblastoma treatment drug market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glioblastoma treatment drug market?

Answer: The major drivers for this market are rising prevalence of glioblastoma, growing adoption of gene and cell therapies, and expanding development of chemotherapy drugs.

Q4. What are the major segments for glioblastoma treatment drug market?

Answer: The future of the glioblastoma treatment drug market looks promising with opportunities in the hospital, cancer research organization, long term care center, and diagnostic center markets.

Q5. Who are the key glioblastoma treatment drug market companies?

Answer: Some of the key glioblastoma treatment drug companies are as follows:
  • Gene Therapy
  • Virus
  • Kinase Inhibitor
  • Glioma Steam Cell Targeting
  • MiRNA Targeting
  • Pfizer
  • Roche Holding
  • Novartis
  • Johnson & Johnson
  • Merck
Q6. Which glioblastoma treatment drug market segment will be the largest in future?

Answer: Lucintel forecasts that alkylating agent will remain the largest segment over the forecast period.

Q7. In glioblastoma treatment drug market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the glioblastoma treatment drug market by drug class (antineoplastic, VEGF/VEGFR inhibitors, alkylating agents, and miscellaneous antineoplastic), distribution channel (hospitals, cancer research organizations, long term care centers, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order.


1. Executive Summary
2. Global Glioblastoma Treatment Drug Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Glioblastoma Treatment Drug Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Glioblastoma Treatment Drug Market by Drug Class
3.3.1: Antineoplastic
3.3.2: VEGF/VEGFR Inhibitors
3.3.3: Alkylating Agents
3.3.4: Miscellaneous Antineoplastic
3.4: Global Glioblastoma Treatment Drug Market by Distribution Channel
3.4.1: Hospitals
3.4.2: Cancer Research Organizations
3.4.3: Long Term Care Centers
3.4.4: Diagnostic Centers
3.4.5: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Glioblastoma Treatment Drug Market by Region
4.2: North American Glioblastoma Treatment Drug Market
4.2.1: North American Glioblastoma Treatment Drug Market by Drug Class: Antineoplastic, VEGF/VEGFR Inhibitors, Alkylating Agents, and Miscellaneous Antineoplastic
4.2.2: North American Glioblastoma Treatment Drug Market by Distribution Channel: Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers, and Others
4.3: European Glioblastoma Treatment Drug Market
4.3.1: European Glioblastoma Treatment Drug Market by Drug Class: Antineoplastic, VEGF/VEGFR Inhibitors, Alkylating Agents, and Miscellaneous Antineoplastic
4.3.2: European Glioblastoma Treatment Drug Market by Distribution Channel: Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers, and Others
4.4: APAC Glioblastoma Treatment Drug Market
4.4.1: APAC Glioblastoma Treatment Drug Market by Drug Class: Antineoplastic, VEGF/VEGFR Inhibitors, Alkylating Agents, and Miscellaneous Antineoplastic
4.4.2: APAC Glioblastoma Treatment Drug Market by Distribution Channel: Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers, and Others
4.5: ROW Glioblastoma Treatment Drug Market
4.5.1: ROW Glioblastoma Treatment Drug Market by Drug Class: Antineoplastic, VEGF/VEGFR Inhibitors, Alkylating Agents, and Miscellaneous Antineoplastic
4.5.2: ROW Glioblastoma Treatment Drug Market by Distribution Channel: Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Glioblastoma Treatment Drug Market by Drug Class
6.1.2: Growth Opportunities for the Global Glioblastoma Treatment Drug Market by Distribution Channel
6.1.3: Growth Opportunities for the Global Glioblastoma Treatment Drug Market by Region
6.2: Emerging Trends in the Global Glioblastoma Treatment Drug Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Glioblastoma Treatment Drug Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glioblastoma Treatment Drug Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Gene Therapy
7.2: Virus
7.3: Kinase Inhibitor
7.4: Glioma Steam Cell Targeting
7.5: MiRNA Targeting
7.6: Pfizer
7.7: Roche Holding
7.8: Novartis
7.9: Johnson & Johnson
7.10: Merck

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings